Structure Therapeutics GSBR-1290 Review

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

Retatrutide, a triple agonist, showed significant reductions in A1C and weight in its first Phase 3 trial for type 2 diabetes.
Orforglipron, an oral GLP-1, helped participants maintain all but 0.9 kg of previously achieved weight loss when switching from Wegovy.
Lilly's orforglipron delivered an average weight loss of up to 27.3 lbs in one Phase 3 trial for adults with obesity.
Orforglipron has been submitted to the U.S. Food and Drug Administration for obesity treatment.

Structure Therapeutics GSBR-1290 represents a new wave of oral GLP-1 medications aimed at managing weight loss and diabetes. While GSBR-1290 is still in development, other oral GLP-1s like Lilly's orforglipron have already shown promising results in clinical trials. For example, orforglipron delivered weight loss of up to an average of 27.3 lbs in one of its pivotal Phase 3 trials for adults with obesity, offering a non-injectable alternative to existing treatments [https://hfsa.org/lillys-oral-glp-1-orforglipron-delivers-weight-loss-average-273-lbs-first-two-pivotal-phase-3]. These oral options could change how people approach long-term treatment for obesity and type 2 diabetes, making it easier to stick with therapy. The convenience of a pill, compared to injections, could significantly improve patient adherence and overall treatment success.

What is GSBR-1290 and how does it compare to other GLP-1s?

GSBR-1290 is an oral GLP-1 medication currently being developed by Structure Therapeutics. It aims to offer a new way for people to manage their weight and diabetes without needing injections. This oral approach is similar to other new medications, such as Lilly's orforglipron, which has already shown strong results in clinical trials. The goal for these oral medications is to provide the same benefits as injectable GLP-1s but in a more convenient pill form.

The Rise of Oral GLP-1s

The development of oral GLP-1s like GSBR-1290 and orforglipron marks an important shift in treatment options. For many years, GLP-1 medications were only available as injections. While effective, injections can be a barrier for some patients, making it harder to start or continue treatment. An oral pill can remove this barrier, potentially making these powerful medications more accessible to a wider range of people who need them for weight management or type 2 diabetes.

Comparing Oral GLP-1 Efficacy

When we look at the potential of oral GLP-1s, we can draw comparisons to the data already available for other candidates. Lilly's orforglipron, for instance, has demonstrated significant weight loss in its Phase 3 trials. In one pivotal Phase 3 trial, adults with obesity achieved an average weight loss of up to 27.3 lbs with orforglipron [https://hfsa.org/lillys-oral-glp-1-orforglipron-delivers-weight-loss-average-273-lbs-first-two-pivotal-phase-3]. This level of efficacy is comparable to what has been seen with injectable GLP-1s. It suggests that oral forms can deliver similar powerful results. If GSBR-1290 can achieve similar outcomes, it would be a major development for patients seeking non-injectable options.

The Mechanism of Action for Oral GLP-1s

GLP-1 receptor agonists work by mimicking a natural hormone in the body called glucagon-like peptide-1. This hormone helps regulate blood sugar levels and can also reduce appetite, leading to weight loss. Oral GLP-1s are designed to be absorbed through the digestive system, allowing them to activate these receptors in the same way as injectable versions. The challenge in developing oral forms is ensuring that the medication can survive the harsh environment of the stomach and be absorbed effectively into the bloodstream. Advancements in drug delivery technology have made this possible, paving the way for drugs like GSBR-1290.

Patient Preferences and Adherence

The convenience factor of an oral medication cannot be overstated. Many patients prefer taking a pill over giving themselves an injection, even if the injection is infrequent. This preference can lead to better adherence to treatment plans, which is crucial for long-term health outcomes in conditions like obesity and type 2 diabetes. When patients are more likely to stick with their medication, they are more likely to experience the full benefits, including sustained weight loss and improved blood sugar control. The introduction of oral GLP-1s like GSBR-1290 offers a patient-friendly alternative that could significantly impact the landscape of obesity and diabetes treatment.

Future Outlook for Oral GLP-1s

The success of oral GLP-1s like orforglipron in clinical trials suggests a bright future for this class of medications. As more oral options become available, it will provide healthcare providers with a broader toolkit to address the diverse needs and preferences of their patients. While specific data for GSBR-1290 is still emerging, its development alongside other promising oral GLP-1s indicates a strong trend towards making these effective treatments more accessible and convenient. The potential for these medications to simplify daily routines while delivering significant health benefits is a key driver behind their ongoing development and anticipated impact on public health.

What are the benefits of oral GLP-1 medications?

Oral GLP-1 medications offer several significant benefits, primarily centered around convenience and patient preference. They provide a non-injectable option for patients who may be hesitant or unable to administer weekly or daily injections. Beyond convenience, these oral forms have demonstrated safety profiles that are consistent with their injectable counterparts, making them a reliable choice for long-term treatment.

Enhanced Patient Convenience and Accessibility

One of the most obvious advantages of oral GLP-1s is the ease of administration. Taking a pill once a day, or even once a week, is often preferred over injections. This can remove a major barrier for many individuals who require these medications for weight management or type 2 diabetes. The convenience of an oral pill can also simplify travel and daily routines, integrating more easily into a patient's lifestyle. This improved accessibility can lead to more people starting and staying on treatment, ultimately improving public health outcomes.

Consistent Safety Profiles

Clinical trials for oral GLP-1 medications have shown that their safety profiles are consistent with injectable GLP-1 medicines. For instance, Lilly's orforglipron demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in a successful Phase 3 trial [https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically]. This means that while the delivery method is different, patients can expect similar side effects, which commonly include gastrointestinal issues like nausea, vomiting, and diarrhea. These side effects are generally mild to moderate and tend to decrease over time as the body adjusts to the medication. The consistency in safety data is reassuring for both patients and healthcare providers.

Potential for Broader Adoption

The development of oral GLP-1s like GSBR-1290 and orforglipron could lead to broader adoption of GLP-1 therapies. Many people living with obesity or type 2 diabetes may avoid treatment due to a fear of needles or the perceived inconvenience of injections. By offering an effective oral alternative, more individuals might be willing to try and stick with these life-changing medications. Increased adoption means more people can benefit from significant weight loss, improved blood sugar control, and reduced risk factors for related health conditions. This wider reach is a critical public health benefit.

Maintaining Weight Loss with Oral Options

Beyond initial weight loss, the ability of oral GLP-1s to help maintain that loss is another key benefit. Long-term adherence is essential for sustained results, and the convenience of a pill supports this. Studies have shown that oral GLP-1s can effectively maintain weight reduction. For example, in a first-of-its-kind Phase 3 trial, orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy [https://www.prnewswire.com/news-releases/lillys-orforglipron-helped-people-maintain-weight-loss-after-switching-from-injectable-incretins-to-oral-glp-1-therapy-in-first-of-its-kind-phase-3-trial-302645471.html]. This demonstrates the long-term utility and benefit of these medications beyond just the initial treatment phase. For more details, see Lilly's retatrutide Phase 3 trial results.

Addressing Unmet Needs

Despite the availability of several effective treatments for obesity and type 2 diabetes, there remains an unmet need for options that are both highly effective and easy to use. Oral GLP-1s directly address this gap. They offer a powerful therapeutic approach without the logistical challenges or psychological barriers associated with injectable drugs. This makes them particularly valuable for patient populations who have struggled with adherence to previous treatment regimens. The ongoing research and development into oral GLP-1s like GSBR-1290 are driven by this crucial need to provide more accessible and sustainable treatment options for chronic conditions.

Impact on Healthcare Systems

The introduction of oral GLP-1s could also have a positive impact on healthcare systems. While the exact cost structures are yet to be fully determined, increased patient adherence could lead to better health outcomes, potentially reducing the need for more intensive or costly interventions down the line. Furthermore, the simplicity of prescribing and managing an oral medication might streamline clinical workflows, allowing healthcare providers to focus more on patient care rather than injection training or supply management. These broader implications highlight the multifaceted benefits that oral GLP-1s bring to the table.

How does orforglipron help maintain weight loss?

Orforglipron, an oral GLP-1 medication, has been specifically studied for its ability to help people maintain weight loss, especially after they have already lost weight using other injectable incretin therapies. The research shows that participants who switched to orforglipron from other injectable medications were able to keep most of their weight off, demonstrating its effectiveness as a long-term maintenance option.

Sustaining Weight Reduction After Initial Loss

Maintaining weight loss is often more challenging than achieving it initially. This is where medications like orforglipron can play a crucial role. In a Phase 3 trial called ATTAIN-MAINTAIN, orforglipron achieved its primary and all key secondary endpoints for weight maintenance when compared to a placebo over 52 weeks. This trial specifically looked at participants who had already lost weight on other medications like Wegovy or Zepbound. The ability of orforglipron to help sustain this loss is a significant finding.

Seamless Transition from Injectable Therapies

A key feature of orforglipron's role in weight maintenance is its ability to facilitate a smooth transition from injectable incretin therapies. The ATTAIN-MAINTAIN study showed that participants who switched to orforglipron from Wegovy maintained almost all of their previously achieved weight loss. On average, they maintained all but 0.9 kg of their weight loss [https://www.prnewswire.com/news-releases/lillys-orforglipron-helped-people-maintain-weight-loss-after-switching-from-injectable-incretins-to-oral-glp-1-therapy-in-first-of-its-kind-phase-3-trial-302645471.html]. This is a remarkable outcome, suggesting that patients can move from an injectable regimen to an oral one without significant rebound weight gain. This flexibility in treatment options can greatly enhance patient satisfaction and adherence over the long term.

The Importance of Long-Term Adherence

The convenience of an oral medication like orforglipron is a major factor in improving long-term adherence. When patients find their medication regimen easy to follow, they are more likely to continue it consistently. This sustained use is vital for maintaining the metabolic and weight-related benefits achieved during the initial weight loss phase. The fact that orforglipron is an oral small-molecule GLP-1 receptor agonist makes it a practical choice for continuous therapy [https://pubmed.ncbi.nlm.nih.gov/40960239/]. The ease of taking a pill daily, as opposed to self-administering injections, can alleviate treatment fatigue and support consistent medication intake, which is critical for preventing weight regain.

Mechanism Behind Weight Maintenance

Orforglipron, like other GLP-1 receptor agonists, works by mimicking the natural GLP-1 hormone. This action helps to regulate appetite, reduce food intake, and slow gastric emptying, all of which contribute to weight management. When used for maintenance, these mechanisms continue to suppress hunger and promote satiety, helping individuals stick to a reduced-calorie diet without feeling constantly deprived. This ongoing physiological support is essential for counteracting the body's natural tendency to regain lost weight. The consistency of these effects, delivered through a convenient oral form, makes orforglipron a powerful tool for long-term weight control.

Future Implications for Chronic Weight Management

The success of orforglipron in weight maintenance trials has significant implications for how chronic weight management will be approached in the future. It suggests that patients may have more flexibility in their treatment journey, including the option to transition from injectable to oral therapies based on their preferences and needs, without compromising their progress. This development offers hope for individuals seeking sustainable solutions for obesity, a chronic disease that requires long-term management. As more oral GLP-1s like GSBR-1290 progress through development, the options for effective and convenient weight maintenance will likely expand further, providing greater choice and control for patients.

What progress has retatrutide made in clinical trials?

Retatrutide, known as LY3437943, is a triple agonist medication that has made significant progress in its clinical trials, particularly for type 2 diabetes and obesity. It has shown impressive results, including substantial reductions in both A1C levels and body weight, signaling its potential as a powerful new treatment option.

Early Phase 3 Success for Type 2 Diabetes

Retatrutide demonstrated significant reductions in A1C and weight in its first Phase 3 trial for the treatment of type 2 diabetes [https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-demonstrated-significant]. This is a crucial milestone, as Phase 3 trials are typically the final stage before a medication can be submitted for regulatory approval. The dual benefit of reducing A1C, a key marker for blood sugar control, and achieving notable weight loss positions retatrutide as a comprehensive treatment for individuals with type 2 diabetes, many of whom also struggle with obesity. This early success suggests a strong profile for addressing multiple aspects of metabolic health.

Triple Agonist Mechanism

What sets retatrutide apart is its triple agonist action. Unlike many GLP-1 medications that target one or two receptors, retatrutide activates three different incretin receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This multi-targeted approach is believed to contribute to its enhanced efficacy in both blood sugar control and weight reduction. By engaging multiple pathways, retatrutide aims to provide a more robust metabolic response, leading to greater improvements in patient outcomes. This innovative mechanism represents a significant advancement in the field of incretin-based therapies. For more details, see Orforglipron weight loss maintenance data.

Addressing Obesity and Overweight

Beyond type 2 diabetes, retatrutide is also being studied extensively for its potential in treating obesity and overweight. Clinical trials are ongoing to evaluate its effectiveness and safety in participants who have obesity or overweight. One such study, NCT05929066, is listed on ClinicalTrials.gov as "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight" [https://clinicaltrials.gov/study/NCT05929066]. These trials are critical for gathering the comprehensive data needed to understand the full scope of retatrutide's benefits for weight management as a standalone indication. The focus on obesity highlights the growing recognition of this condition as a chronic disease requiring effective medical interventions.

Detailed Clinical Trial Design

The ongoing studies for retatrutide involve rigorous design to ensure thorough evaluation. These studies typically include a large number of participants, often with specific eligibility criteria such as age groups (e.g., older adults 65+) and health status (e.g., presence of obesity or overweight). They employ various arm types, including experimental arms where participants receive retatrutide, and may also include active comparator or placebo comparator arms. Data collected at baseline, such as demographics and specific health measures, are used to track changes throughout the trial. The careful monitoring of adverse events is also a standard practice to assess the safety profile of the medication. This meticulous approach ensures that the findings are reliable and provide a clear picture of retatrutide's effects.

Future Expectations for Retatrutide

The promising results from retatrutide's initial Phase 3 trial for type 2 diabetes, combined with ongoing studies for obesity, suggest that it could become a significant player in the GLP-1 landscape. Its triple agonist mechanism offers a novel approach that may provide superior benefits compared to single or dual agonists. As more data emerges from the ongoing trials, especially those focused on weight management, we will gain a clearer understanding of its full potential. The development of retatrutide underscores the continuous innovation in the field of metabolic medicine, bringing new hope to millions affected by type 2 diabetes and obesity. The focus on both A1C and weight reduction addresses two critical aspects of these interconnected health challenges, offering a holistic treatment perspective.

Is orforglipron approved for use?

Orforglipron has completed its Phase 3 clinical trials, showing strong efficacy and a safety profile consistent with existing GLP-1 medications. Following these successful trials, Lilly has submitted orforglipron to the U.S. Food and Drug Administration (FDA) for the treatment of obesity, indicating it is currently under review for approval.

Completion of Pivotal Phase 3 Trials

Lilly's oral GLP-1, orforglipron, has successfully completed pivotal Phase 3 trials. These trials are the final and most extensive stage of clinical testing before a drug can be considered for market approval. In one of these trials, orforglipron delivered weight loss of up to an average of 27.3 lbs in adults with obesity [https://hfsa.org/lillys-oral-glp-1-orforglipron-delivers-weight-loss-average-273-lbs-first-two-pivotal-phase-3]. Another Phase 3 trial, ATTAIN-MAINTAIN, demonstrated that orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy [https://www.prnewswire.com/news-releases/lillys-orforglipron-helped-people-maintain-weight-loss-after-switching-from-injectable-incretins-to-oral-glp-1-therapy-in-first-of-its-kind-phase-3-trial-302645471.html]. The successful completion of these trials is a crucial step toward making orforglipron available to patients.

Submission to the U.S. Food and Drug Administration

Following the positive results from its Phase 3 program, Lilly has officially submitted orforglipron to the U.S. Food and Drug Administration (FDA) for the treatment of obesity [https://www.prnewswire.com/news-releases/lillys-orforglipron-helped-people-maintain-weight-loss-after-switching-from-injectable-incretins-to-oral-glp-1-therapy-in-first-of-its-kind-phase-3-trial-302645471.html]. This submission means that the FDA is now reviewing all the data collected during the clinical trials, including efficacy, safety, and manufacturing information. The FDA's review process is thorough and can take several months to a year or more, during which they assess whether the drug is safe and effective for its intended use. While it is under review, orforglipron is not yet available for prescription.

Promising Efficacy and Safety Profile

The data submitted to the FDA highlights orforglipron's significant efficacy and a safety profile consistent with injectable GLP-1 medicines. This consistency is important because it suggests that patients can expect similar benefits and manage similar side effects as with established injectable GLP-1s, but with the added convenience of an oral pill. The statistically significant efficacy results from the Phase 3 trials are a strong indicator of its potential to be a valuable treatment option for obesity [https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically]. The detailed findings from studies such as "Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment" further underscore its robust profile [https://pubmed.ncbi.nlm.nih.gov/40960239/].

What FDA Approval Means

If approved by the FDA, orforglipron would become one of the first oral GLP-1 medications specifically indicated for the treatment of obesity. FDA approval would mean that the agency has determined the benefits of the drug outweigh its risks for the target population when used as directed. This would allow healthcare providers to prescribe orforglipron to eligible patients, expanding the range of treatment options available for chronic weight management. Approval would also pave the way for broader access and potential insurance coverage, making the medication more accessible to those who need it.

Anticipated Impact on the Market

The potential approval of orforglipron is highly anticipated in the medical community. It would introduce a convenient oral option into a market currently dominated by injectable GLP-1s. This could significantly increase patient uptake of GLP-1 therapies, as the barrier of injections is removed. For patients who struggle with needle aversion or prefer the simplicity of a pill, orforglipron could be a game-changer. Its availability would offer greater flexibility in treatment choices, empowering patients and their healthcare providers to select the most suitable and sustainable therapy for their individual needs. The ongoing review by the FDA is a critical step towards realizing this potential.

What are the ongoing studies for retatrutide?

There are several ongoing studies for retatrutide (LY3437943), particularly focused on its use in participants who have obesity or are overweight. These studies are crucial for thoroughly evaluating the medication's effectiveness and safety across different patient populations and for various indications.

Comprehensive Evaluation for Obesity and Overweight

One of the key ongoing studies for retatrutide is specifically designed to assess its impact on individuals with obesity or overweight. This study, identified as NCT05929066, is titled "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight" and is publicly listed on ClinicalTrials.gov [https://clinicaltrials.gov/study/NCT05929066]. The primary goal of such studies is to gather robust data on how retatrutide affects body weight, body composition, and other health markers in this patient group. This research is vital for understanding if retatrutide can become a widely used treatment for chronic weight management. For more details, see ClinicalTrials.gov on Retatrutide for obesity/overweight.

Detailed Study Design and Participants

The ongoing studies for retatrutide are designed with rigorous methodologies. They often involve specific eligibility criteria, such as age ranges, body mass index (BMI) thresholds, and overall health status, to ensure that the study population is appropriate for evaluating the drug's effects. Participants are typically assigned to different arms, which might include receiving various doses of retatrutide, a placebo, or an active comparator drug. This allows researchers to compare the outcomes and determine the optimal dosage and efficacy relative to other treatments or no treatment. The studies also collect extensive baseline characteristics, including demographics like age, sex, race, and ethnicity, as well as study-specific measures such as blood pressure or other relevant health indicators.

Monitoring Efficacy Endpoints

In these ongoing trials, researchers are closely monitoring several efficacy endpoints. For participants with obesity or overweight, key endpoints would typically include changes in body weight, waist circumference, and other measures of adiposity. The goal is to see significant and sustained reductions in weight, similar to the promising results observed in the first Phase 3 trial for type 2 diabetes, where retatrutide demonstrated significant reductions in both A1C and weight [https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-demonstrated-significant]. The success in these endpoints is critical for potential regulatory approval for obesity.

Assessing Safety and Tolerability

Beyond efficacy, a major focus of all ongoing clinical trials is to thoroughly assess the safety and tolerability of retatrutide. This involves carefully tracking all adverse events, which are any unfavorable changes in a participant's health that occur during or after the study. Researchers document the type, severity, and frequency of these events to build a comprehensive safety profile for the medication. Understanding the side effects and how they compare to other GLP-1 medications is crucial for determining the overall risk-benefit ratio of retatrutide. The goal is to ensure that the medication is not only effective but also well-tolerated by patients over long periods of use.

The Role of Triple Agonism in Ongoing Research

The ongoing studies also aim to further explore the unique benefits of retatrutide's triple agonist mechanism. By targeting GLP-1, GIP, and glucagon receptors, retatrutide is designed to provide a more potent and comprehensive metabolic effect. The trials will help to confirm whether this multi-faceted approach translates into superior outcomes for weight loss and metabolic health in a broader range of patients. These studies are essential for solidifying the scientific understanding of how triple agonists work and their place in the future of obesity and diabetes treatment. The findings will contribute significantly to the body of knowledge surrounding incretin-based therapies.

Frequently Asked Questions

What is GSBR-1290?

GSBR-1290 is an oral GLP-1 medication currently under development by Structure Therapeutics. It is designed to help with weight loss and diabetes management, offering a pill form instead of injections. While specific trial data for GSBR-1290 is still emerging, other oral GLP-1s like Lilly's orforglipron have shown promising results, such as an average weight loss of up to 27.3 lbs in one Phase 3 trial for adults with obesity [https://hfsa.org/lillys-oral-glp-1-orforglipron-delivers-weight-loss-average-273-lbs-first-two-pivotal-phase-3].

How do oral GLP-1s like orforglipron work?

Oral GLP-1s like orforglipron mimic a natural hormone called glucagon-like peptide-1, which helps regulate blood sugar and reduces appetite. They are designed to be absorbed through the digestive system to activate specific receptors in the body. Orforglipron has demonstrated statistically significant efficacy and a safety profile consistent with injectable GLP-1 medicines in a Phase 3 trial [https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically].

What are the main findings for retatrutide?

Retatrutide, a triple agonist, has shown significant progress in clinical trials. In its first Phase 3 trial for type 2 diabetes, it demonstrated significant reductions in both A1C levels and body weight [https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-demonstrated-significant]. Studies are also ongoing to evaluate its effectiveness in participants who have obesity or are overweight [https://clinicaltrials.gov/study/NCT05929066].

Has orforglipron been approved by the FDA?

Orforglipron has completed its Phase 3 clinical trials and has been submitted to the U.S. Food and Drug Administration (FDA) for the treatment of obesity [https://www.prnewswire.com/news-releases/lillys-orforglipron-helped-people-maintain-weight-loss-after-switching-from-injectable-incretins-to-oral-glp-1-therapy-in-first-of-its-kind-phase-3-trial-302645471.html]. It is currently under review and is not yet approved for use.

Where can I find more information on GLP-1 clinical trials?

You can find more information on GLP-1 clinical trials, including those for medications like retatrutide and orforglipron, on official government and pharmaceutical company websites. ClinicalTrials.gov (e.g., NCT05929066 for retatrutide) and Eli Lilly and Company's investor news releases are good sources for detailed study information and results [https://clinicaltrials.gov/study/NCT05929066].